$14.9M capital deployed

28% primary ownership

Sep '11 initial capital deployed

return to top

Why Putney?

Headquartered in Portland, ME, Putney is a rapidly growing pet pharmaceutical company focused on developing high-quality, generic prescription medicines for pets.

Putney’s mission is to provide veterinary practices with FDA-approved veterinary generic medicines that meet pet medical needs and offer cost-effective alternatives for pet owners.

According to IMS Health, 86% of all human prescriptions in the U.S. are filled with a generic, yet very few generics exist for drugs prescribed for pets. Analysis of FDA Center for Veterinary Medicine approvals reveals that 91% of FDA-approved drugs for pets have no generic equivalent. The overall size of the pet pharmaceutical market is significant. Packaged Facts, in its April 2014 report entitled, “Pet Medications in the U.S.,” stated that the U.S. retail sales of pet medications reached $8 billion in 2013 and projected that the market will grow to more than $10 billion in 2018, reflecting a compound annual growth rate of 5%.

During the first quarter of 2015, Putney announced that it received its fifth FDA approval in five months, which includes Putney Enrofloxacin Antibacterial Injectable Solution (generic of Baytril® Antibacterial Injectable Solution); Putney Carprofen Chewable Tablets (generic of Rimadyl® Chewable Tablets); Putney Dexmedetomidine HCl (generic of Dexdomitor®); Putney Carprofen Sterile Injectable Solution (generic of Rimadyl® Injectable), which Putney commercially launched during the first quarter of 2015; and Putney Meloxicam Solution for Injection (generic of Metacam® Solution for Injection). Putney now sells FDA-approved generic versions of all three Rimadyl® drugs. In addition to Carprofen Sterile Injectable Solution, Putney also offers FDA-approved Carprofen Chewable Tablets and Carprofen Caplets.

(Updated as of 03/31/15)